BioSpace News Archive

HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced that Adrian M. Di Bisceglie, M.D., has been appointed as Chief Medical Officer.

The American Osteopathic Association advises consumers to know the most common culprits to avoid spoiling the fun

The global bone-anchored hearing aids market is expected to post a CAGR close to 12% during the period 2019-2023, according to the latest market research report by Technavio.

Hospital closes gap in neurological cancer care and provides better access for patients in the Hispanic community

MGI, a subsidiary of BGI Group, expressed confidence in its core patent portfolio in the field of gene sequencing and vowed to fully support the industry to achieve higher quality, more cost-effective sequencing.

Cross Country Healthcare, Inc., (Nasdaq: CCRN) a leading provider of healthcare workforce solutions and staffing services nationwide today announced it has merged its signature permanent search brands – Cejka Physician Search, AP Healthcare, StarMed and Cross Country Staffing’s RPO division – under the new Cross Country Search brand.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).

HCP, Inc. (NYSE: HCP) is scheduled to report its second quarter 2019 financial results after the close of trading on the New York Stock Exchange on Wednesday, July 31, 2019.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2019 on Wednesday, July 31, 2019, after the market closes.

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of common stock of OncoCyte Corporation at a price to buyers of $2.00 per share, for gross proceeds totaling $4,500,000, before payment of customary sales commissions and offering expenses.